vs

Side-by-side financial comparison of Datacentrex, Inc. (DTCX) and Opus Genetics, Inc. (IRD). Click either name above to swap in a different company.

Datacentrex, Inc. is the larger business by last-quarter revenue ($7.0M vs $3.9M, roughly 1.8× Opus Genetics, Inc.). On growth, Datacentrex, Inc. posted the faster year-over-year revenue change (4463314.1% vs -10.2%).

Datacentrex, Inc. is a technology infrastructure service provider offering colocation, managed cloud hosting, and enterprise IT support solutions. It serves small, medium and enterprise clients as well as public sector organizations across North America, focusing on reliable, secure data center operations and customized digital infrastructure services.

Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.

DTCX vs IRD — Head-to-Head

Bigger by revenue
DTCX
DTCX
1.8× larger
DTCX
$7.0M
$3.9M
IRD
Growing faster (revenue YoY)
DTCX
DTCX
+4463324.3% gap
DTCX
4463314.1%
-10.2%
IRD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DTCX
DTCX
IRD
IRD
Revenue
$7.0M
$3.9M
Net Profit
$5.3M
Gross Margin
Operating Margin
87.2%
Net Margin
75.8%
Revenue YoY
4463314.1%
-10.2%
Net Profit YoY
295.3%
53.0%
EPS (diluted)
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DTCX
DTCX
IRD
IRD
Q4 25
$7.0M
$3.9M
Q3 25
$3.1M
Q2 25
$2.9M
Q1 25
$4.4M
Q4 24
$4.3M
Q3 24
$3.9M
Q2 24
$1.1M
Q1 24
$1.7M
Net Profit
DTCX
DTCX
IRD
IRD
Q4 25
$5.3M
Q3 25
$-17.5M
Q2 25
$-7.4M
Q1 25
$-8.2M
Q4 24
Q3 24
$-7.5M
Q2 24
$-7.8M
Q1 24
$-7.1M
Operating Margin
DTCX
DTCX
IRD
IRD
Q4 25
87.2%
Q3 25
-269.9%
Q2 25
-309.0%
Q1 25
-227.2%
Q4 24
Q3 24
-207.1%
Q2 24
-748.9%
Q1 24
-450.5%
Net Margin
DTCX
DTCX
IRD
IRD
Q4 25
75.8%
Q3 25
-566.9%
Q2 25
-257.5%
Q1 25
-187.5%
Q4 24
Q3 24
-194.6%
Q2 24
-698.3%
Q1 24
-415.3%
EPS (diluted)
DTCX
DTCX
IRD
IRD
Q4 25
$0.65
Q3 25
$-0.25
Q2 25
$-0.12
Q1 25
$-0.24
Q4 24
Q3 24
$-0.29
Q2 24
$-0.30
Q1 24
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DTCX
DTCX
IRD
IRD
Cash + ST InvestmentsLiquidity on hand
$38.9M
$45.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$66.2M
$15.3M
Total Assets
$66.8M
$50.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DTCX
DTCX
IRD
IRD
Q4 25
$38.9M
$45.1M
Q3 25
$30.8M
Q2 25
$32.4M
Q1 25
$41.8M
Q4 24
$30.3M
Q3 24
$36.6M
Q2 24
$41.4M
Q1 24
$47.2M
Stockholders' Equity
DTCX
DTCX
IRD
IRD
Q4 25
$66.2M
$15.3M
Q3 25
$6.0M
Q2 25
$17.5M
Q1 25
$5.1M
Q4 24
$6.7M
Q3 24
$34.3M
Q2 24
$40.6M
Q1 24
$46.1M
Total Assets
DTCX
DTCX
IRD
IRD
Q4 25
$66.8M
$50.2M
Q3 25
$36.1M
Q2 25
$38.7M
Q1 25
$48.2M
Q4 24
$36.9M
Q3 24
$40.4M
Q2 24
$44.8M
Q1 24
$51.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DTCX
DTCX
IRD
IRD
Operating Cash FlowLast quarter
$-1.5M
$-35.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.28×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DTCX
DTCX
IRD
IRD
Q4 25
$-1.5M
$-35.3M
Q3 25
$-6.2M
Q2 25
$-10.3M
Q1 25
$-9.0M
Q4 24
$-25.6M
Q3 24
$-5.1M
Q2 24
$-7.3M
Q1 24
$-5.7M
Cash Conversion
DTCX
DTCX
IRD
IRD
Q4 25
-0.28×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons